Castle Biosciences Reports Strong Q3 2024 Performance
Company Announcements

Castle Biosciences Reports Strong Q3 2024 Performance

Castle Biosciences ( (CSTL) ) just unveiled an announcement.

Castle Biosciences reported a robust third quarter for 2024, with revenues surging by 39% to $86 million and a 41% increase in total test reports compared to the same quarter last year. The company attributes this success to the strong adoption of their diagnostic tests, driven by enhanced clinical evidence, particularly for DecisionDx®-SCC and other core products. Castle Biosciences has raised its full-year revenue guidance, projecting significant growth and profitability, showcasing the effectiveness of their business model and dedication to creating value for patients, clinicians, and shareholders.

Find detailed analytics on CSTL stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCastle Biosciences price target raised to $44 from $37 at Scotiabank
TipRanks Auto-Generated NewsdeskCastle Biosciences Faces Financial Strain Amid 2024 Loan Covenant Restrictions
TheFlyCastle Biosciences price target raised to $45 from $40 at BTIG
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App